Button

Button is a Mountain View-based life sciences and medical technology company that functions as a venture partner and strategic advisor. It focuses on early-stage ventures in the medical technology and life sciences sectors and supports them through three activities: investment to facilitate startup growth; advisory services to executives pursuing entry or expansion in China; and Button Analytics, which provides deal sourcing and market-trend analysis from a proprietary data platform. Button aims to advance therapies and diagnostic solutions in areas such as women's health, cardiovascular disease, orthopedics, and cancer, and helps life sciences and healthcare companies leverage capital, partnerships, and data-driven insights to succeed in China.

Xi Fang

Founding Partner

Leroy Li

Managing Partner

6 past transactions

Xcision Medical Systems

Series B in 2021
Xcision Medical Systems, LLC is a medical technology company focused on developing innovative stereotactic radiotherapy solutions aimed at enhancing cancer treatment. The company specializes in manufacturing radiosurgery devices specifically designed for breast cancer treatment. Its technology utilizes stereotactic gamma irradiation, allowing for a complete course of radiation therapy to be delivered in a single, noninvasive session. This approach significantly reduces the duration of treatment compared to traditional methods, while minimizing radiation exposure to surrounding healthy tissues, including the lungs and heart. As a result, patients can resume their daily activities more quickly and with less discomfort, ultimately improving their quality of life. Additionally, Xcision's advancements enable healthcare professionals to enhance the overall quality of cancer care they provide.

Quest Genomics

Series C in 2020
Nanjing Quest Genomics Co., Ltd. specializes in the research, development, and production of instruments and reagents for tumor gene detection, with a particular emphasis on tumor liquid biopsy. Founded in 2012 and headquartered in Nanjing, China, the company is dedicated to advancing genetic testing technologies, particularly in the areas of digital PCR and next-generation sequencing (NGS). Quest Genomics has developed a range of products for detecting mutations in key genes, including HER2, PIK3CA, EGFR, and KRAS, aimed at facilitating targeted therapy and monitoring minimal residual disease (MRD) in cancer patients. Their solutions support the early diagnosis of tumor recurrence, metastasis, and disease progression, thereby enhancing treatment outcomes. Additionally, the company maintains a technology development and overseas market center in San Diego, California, to bolster its global reach and innovation capabilities.

EPINTEK

Series B in 2020
Epintek is a company focused on the biomedical and medical device sectors, specializing in contract research organization (CRO) services. It offers a range of services including preclinical research, inspection, and testing for medical institutions and equipment manufacturers. By providing integrated regulatory services, Epintek assists clients with registration and clinical trial processes, ensuring reliable and thorough preclinical inspection of medical devices. Its expertise supports the development and compliance of innovative healthcare solutions.

Sinorda Biomedicine

Series A in 2019
Sinorda Biomedicine, headquartered in China, specializes in innovative drug development. Its primary focus is on small molecule drugs and T cell cancer immunotherapeutics.

ibanker

Seed Round in 2018
iBanker is an education management startup based in Beijing that focuses on financial online education. The company aims to be the premier learning platform for financial and quasi-financial practitioners in China. iBanker offers a wide range of multi-tier financial practice courses, covering topics such as investment banking, industry research, asset management, and financial analysis. This diverse curriculum is designed to meet the educational needs of users across various workplaces, enhancing their professional skills and knowledge in the financial sector.

Lakebio

Seed Round in 2017
LAKEbio to provide a series of liquid biopsies preservation products based on gene detection and other new technologies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.